



## **Integra LifeSciences to Present at the 28th Annual J.P. Morgan Healthcare Conference**

PLAINSBORO, N.J., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Mr. Stuart Essig, President and Chief Executive Officer of Integra, will present on Wednesday, January 13th at 3:30 PM PT. A webcast will be available for this conference via a link on our Investor Relations website at <http://investor.integra-ls.com/> under the Events & Presentations section. A replay of the webcast will be available for 90 days following the live event.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit [www.Integra-LS.com](http://www.Integra-LS.com).

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT: Integra LifeSciences Holdings Corporation  
John B. Henneman, III, Executive Vice President and Chief  
Financial Officer  
(609) 275-0500  
[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)  
Investor Relations:  
Angela Steinway, Finance and Administration  
(609) 936-2268  
[angela.steinway@integra-LS.com](mailto:angela.steinway@integra-LS.com)

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.